Zevra Therapeutics announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer. Dr. Quartel was previously the Chief Medical Officer of Acer Therapeutics – Recently acquired by Zevra -, where he played a key role in guiding clinical development, medical affairs and regulatory compliance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZVRA:
- Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer
- Zevra Therapeutics price target raised to $15 from $10 at H.C. Wainwright
- Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
- Zevra Therapeutics resubmits NDA for arimoclomol
- Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
